Processing

Please wait...

Settings

Settings

Goto Application

1. WO2017023672 - 4-(3-PYRAZOLYLAMINO)-BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS JAK1 INHIBITORS

Publication Number WO/2017/023672
Publication Date 09.02.2017
International Application No. PCT/US2016/044410
International Filing Date 28.07.2016
IPC
C07D 403/12 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
A61K 31/4184 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
4184condensed with carbocyclic rings, e.g. benzimidazoles
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 31/4184
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
41641,3-Diazoles
4184condensed with carbocyclic rings, e.g. benzimidazoles
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
C07D 403/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
Applicants
  • ELI LILLY AND COMPANY [US]/[US]
Inventors
  • CLAYTON, Joshua Ryan
Agents
  • HOSTETTLER, Danica
  • BARRETT, Brian
Priority Data
62/200,68404.08.2015US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) 4-(3-PYRAZOLYLAMINO)-BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS JAK1 INHIBITORS
(FR) COMPOSÉS 4-(3-PYRAZOLYLAMINO)-BENZIMIDAZOLE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE JAK1
Abstract
(EN)
The present invention relates to certain benzimidazole compounds of Formula I, or pharmaceutically acceptable salts thereof, that inhibit Janus kinase 1 (JAKI), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat certain types of cancer.
(FR)
La présente invention concerne certains composés de benzimidazole de Formule I, ou des sels pharmaceutiquement acceptables de ceux-ci, qui inhibent la janus kinase 1 (JAKI), des compositions pharmaceutiques comprenant les composés et des procédés d'utilisation des composés pour traiter certains types de cancer.
Latest bibliographic data on file with the International Bureau